Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors

The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity

Stanietsky, N., Simic, H., Arapovic, J., Toporik, A., Levy, O., Novik, A., Levine, Z., Beiman, M., Dassa, L., Achdout, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903474106 · Cited by 3,524 · see citing works

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380 · see citing works

In search of the ‘missing self’: MHC molecules and NK cell recognition

Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687 · see citing works

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910607 · Cited by 2,217 · see citing works

Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation

Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096 · see citing works

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835 · see citing works

Adaptive Immune Features of Natural Killer Cells

Sun, J. C., Beilke, J., & Lanier, L. (2009) · Nature · doi:10.1038/nature07665 · Cited by 1,647 · see citing works

Immune surveillance of tumors

Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,469 · see citing works

The C‐type lectin‐like domain superfamily

Zelensky, A. N., & Gready, J. E. (2005) · FEBS Journal · doi:10.1111/j.1742-4658.2005.05031.x · Cited by 1,411 · see citing works

Licensing of natural killer cells by host major histocompatibility complex class I molecules

Kim, S., Poursine‐Laurent, J., Truscott, S. M., Lybarger, L. P., Song, Y.-J., Yang, L., French, A. R., Sunwoo, J. B., Lemieux, S., Hansen, T. H., et al. (2005) · Nature · doi:10.1038/nature03847 · Cited by 1,328 · see citing works

Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma

Weng, W., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · see citing works

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

André, P., Denis, C., Soulas, C., Bourbon, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.014 · Cited by 1,229 · see citing works

Human NK Cell Education by Inhibitory Receptors for MHC Class I

Anfossi, N., André, P., Guia, S., Falk, C. S., Roetynck, S., Stewart, C. A., Breso, V., Frassati, C., Reviron, D., Middleton, D., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.013 · Cited by 1,207 · see citing works

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Qin, S., Xu, L., Yi, M., Yu, S., Wu, K., & Luo, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1091-2 · Cited by 1,145 · see citing works

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

Zhang, Q., Bi, J., Zheng, X., Chen, Y., Wang, H., Wu, W., Wang, Z., Wu, Q., Peng, H. C., Wei, H., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0132-0 · Cited by 1,122 · see citing works

Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity

Li, Y., Hermanson, D., Moriarity, B. S., & Kaufman, D. S. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.06.002 · Cited by 986 · see citing works

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia

Romee, R., Rosario, M., Berrien-Elliott, M. M., Wagner, J. A., Jewell, B. A., Schappe, T., Leong, J. W., Abdel-Latif, S., Schneider, S. E., Willey, S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2341 · Cited by 944 · see citing works

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity

Liu, E., Tong, Y., Dotti, G., Shaim, H., Savoldo, B., Mukherjee, M., Orange, J. S., Wan, X., Lu, X. Y., Reynolds, A., et al. (2017) · Leukemia · doi:10.1038/leu.2017.226 · Cited by 822 · see citing works

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817 · see citing works

TIGIT in cancer immunotherapy

Chauvin, J.-M., & Zarour, H. M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000957 · Cited by 808 · see citing works

CAR-NK cells: A promising cellular immunotherapy for cancer

Xie, G., Dong, H., Liang, Y., Ham, J. D., Rizwan, R., & Chen, J. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102975 · Cited by 800 · cited 2× · see citing works

FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype

Koene, H. R., Kleijer, M., Algra, J., Roos, D., Borne, A. E. G. K. V. D., & de Haas, M. (1997) · Blood · doi:10.1182/blood.v90.3.1109 · Cited by 796 · see citing works

Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function

Schlums, H., Cichocki, F. M., Tesi, B., Theorell, J., Béziat, V., Holmes, T. D., Han, H., Chiang, S. C. C., Foley, B. A., Mattsson, K., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.02.008 · Cited by 791 · see citing works

Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FeγRIIB

Ono, M., Bolland, S. M., Tempst, P., & Ravetch, J. V. (1996) · Nature · doi:10.1038/383263a0 · Cited by 781 · see citing works

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

D'Angelo, S. P., Mahoney, M. R., Van Tine, B. A., Atkins, J., Milhem, M. M., Jahagirdar, B. N., Antonescu, C. R., Horvath, E., Tap, W. D., Schwartz, G. K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30006-8 · Cited by 759 · see citing works

A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease.

Wu, J., Edberg, J. C., Redecha, P. B., Bansal, V., Guyre, P. M., Coleman, K. D., Salmon, J. E., & Kimberly, R. P. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119616 · Cited by 711 · see citing works

Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma

Zhou, Y., Yang, D., Yang, Q., Lv, X., Huang, W., Zhou, Z., Wang, Y., Zhang, Z., Yuan, T., Ding, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20059-6 · Cited by 672 · see citing works

Recruitment of Tyrosine Phosphatase HCP by the Killer Cell Inhibitory Receptor

Burshtyn, D. N., Scharenberg, A. M., Wagtmann, N. R., Rajagopalan, S., Berrada, K., Yi, T., Kinet, J., & Long, E. O. (1996) · Immunity · doi:10.1016/s1074-7613(00)80300-3 · Cited by 613 · see citing works

A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules

Fernandez, N. C., Treiner, E., Vance, R. E., Jamieson, A. M., Lemieux, S., & Raulet, D. H. (2005) · Blood · doi:10.1182/blood-2004-08-3156 · Cited by 589 · see citing works

Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity

Ndhlovu, L. C., López‐Vergès, S., Barbour, J. D., Jones, R. B., Jha, A. R., Long, B. R., Schoeffler, E. C., Fujita, T., Nixon, D. F., & Lanier, L. L. (2012) · Blood · doi:10.1182/blood-2011-11-392951 · Cited by 512 · see citing works

NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation

Gilfillan, S., Ho, E. L., Cella, M., Yokoyama, W. M., & Colonna, M. (2002) · Nature Immunology · doi:10.1038/ni857 · Cited by 437 · see citing works

Direct Binding and Functional Transfer of NK Cell Inhibitory Receptors Reveal Novel Patterns of HLA-C Allotype Recognition

Winter, C. C., Gumperz, J. E., Parham, P., Long, E. O., & Wagtmann, N. R. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.2.571 · Cited by 418 · see citing works

γ/δ T-Cell Stimulation by Pamidronate

Kunzmann, V., Bauer, E., & Wilhelm, M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400914 · Cited by 397 · see citing works

Tim-3 finds its place in the cancer immunotherapy landscape

Acharya, N., Sabatos-Peyton, C. A., & Anderson, A. C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000911 · Cited by 397 · see citing works

Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15.

Johnston, J. A., Bacon, C. M., Finbloom, D. S., Rees, R. C., Kaplan, D. H., Shibuya, K., Ortaldo, J. R., Gupta, S. R., Chen, Y. Q., & Giri, J. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8705 · Cited by 391 · see citing works

Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation

Pende, D., Falco, M., Vitale, M., Cantoni, C., Vitale, C., Munari, E., Bertaina, A., Moretta, F., Zotto, G. D., Pietra, G., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01179 · Cited by 390 · see citing works

NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects

Olson, J. A., Leveson-Gower, D. B., Gill, S. I., Baker, J. B., Beilhack, A., & Negrin, R. S. (2010) · Blood · doi:10.1182/blood-2009-05-222190 · Cited by 387 · see citing works

The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy

Long, L., Zhang, X., Chen, F., Pan, Q., Phiphatwatchara, P., Zeng, Y., & Chen, H. (2018) · Genes & Cancer · doi:10.18632/genesandcancer.180 · Cited by 386 · see citing works

Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor

Ruffo, E., Wu, R. C., Bruno, T. C., Workman, C. J., & Vignali, D. A. A. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101305 · Cited by 381 · see citing works

Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity

Pende, D., Marcenaro, S., Falco, M., Martini, S., Bernardo, M. E., Montagna, D., Romeo, E., Cognet, C., Martinetti, M., Maccario, R., et al. (2008) · Blood · doi:10.1182/blood-2008-06-164103 · Cited by 374 · see citing works

Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9

Gleason, M., Lenvik, T. R., McCullar, V., Felices, M., O'Brien, M., Cooley, S., Verneris, M. R., Cichocki, F. M., Holman, C., Panoskaltsis‐Mortari, A., et al. (2012) · Blood · doi:10.1182/blood-2011-06-360321 · Cited by 372 · see citing works

Human and mouse killer-cell inhibitory receptors recruit PTP1C and PTP1D protein tyrosine phosphatases

Olcese, L., Lang, P., Vely, F., Cambiaggi, A., Marguet, D., Bléry, M., Hippen, K. L., Biassoni, R., Moretta, A., Moretta, L., et al. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.12.4531 · Cited by 360 · see citing works

NK Cell-Based Immune Checkpoint Inhibition

Khan, M. B., Arooj, S., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00167 · Cited by 359 · see citing works

Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells

Liu, S., Zhang, H., Li, M., Hu, D., Li, C., Ge, B.-X., Jin, B., & Fan, Z. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.141 · Cited by 341 · see citing works

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM

Hung, A. L., Maxwell, R., Theodros, D., Belcaid, Z., Mathios, D., Luksik, A. S., Kim, E. S., Wu, A., Xia, Y., Garzón-Muvdi, T., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1466769 · Cited by 337 · see citing works

Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells

Kamiya, T., Seow, S. V., Wong, D., Robinson, M., & Campana, D. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123955 · Cited by 337 · see citing works

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

Nazha, B., Inal, C., & Owonikoko, T. K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01000 · Cited by 334 · see citing works

Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function

Lee, Y.-H., Martin-Orozco, N., Zheng, P., Li, J., Zhang, P., Tan, H., Park, H. J., Jeong, M., Chang, S. H., Kim, B.-S., et al. (2017) · Cell Research · doi:10.1038/cr.2017.90 · Cited by 328 · see citing works

Direct Assessment of MHC Class I Binding by Seven Ly49 Inhibitory NK Cell Receptors

Hanke, T., Takizawa, H., McMahon, C. W., Busch, D. H., Pamer, E. G., Miller, J. D., Altman, J. D., Liu, Y., Cado, D., Lemonnier, F. A., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80082-5 · Cited by 308 · see citing works

Characterization of the major histocompatibility complex class II binding site on LAG-3 protein

Huard, B., Mastrangeli, R., Prigent, P., Bruniquel, D., Donini, S., Tayar, N. E., Maigret, B., Dréano, M., & Triebel, F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5744 · Cited by 308 · see citing works

Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.

Asai, O., Longo, D. L., Tian, Z., Hornung, R. L., Taub, D. D., Ruscetti, F. W., & Murphy, W. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1268 · Cited by 300 · see citing works

Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis

Heczey, A. A., Courtney, A. N., Montalbano, A., Robinson, S. N., Ka, L., Li, M., Ghatwai, N., Dakhova, O., Liu, B., Raveh-Sadka, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1074-2 · Cited by 287 · see citing works

Developmental and Functional Control of Natural Killer Cells by Cytokines

Wu, Y., Tian, Z., & Wei, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00930 · Cited by 269 · see citing works

Natural Killer Cell-Mediated Killing of Freshly Isolated Neuroblastoma Cells

Castriconi, R., Dondero, A., Corrias, M. V., Lanino, E., Pende, D., Moretta, L., Bottino, C., & Moretta, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2682 · Cited by 257 · see citing works

NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors

Parihar, R., Rivas, C. H., Huynh, M., Omer, B. A., Lapteva, N., Metelitsa, L. S., Gottschalk, S. M., & Rooney, C. M. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0572 · Cited by 254 · see citing works

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

Yu, A. L., Uttenreuther-Fischer, M. M., Huang, C. S., Tsui, C. C., Gillies, S. D., Reisfeld, R. A., & Kung, F. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2169 · Cited by 250 · see citing works

Canine Osteosarcoma: A Naturally Occurring Disease to Inform Pediatric Oncology

Fenger, J. M., London, C. A., & Kisseberth, W. C. (2014) · ILAR Journal · doi:10.1093/ilar/ilu009 · Cited by 248 · see citing works

The NKG2A–HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment

Borst, L., van der Burg, S. H., & van Hall, T. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2095 · Cited by 245 · see citing works

TIM-3, a promising target for cancer immunotherapy

He, Y., Cao, J., Zhao, C., Li, X., Zhou, C., & Hirsch, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s170385 · Cited by 235 · see citing works

Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors

Cho, D., Shook, D. R., Shimasaki, N., Chang, Y.-H., Fujisaki, H., & Campana, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0735 · Cited by 233 · see citing works

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

Tarek, N., Luduec, J.-B. L., Gallagher, M. M., Zheng, J., Venstrom, J. M., Chamberlain, E., Modak, S. I., Heller, G., Dupont, B., Cheung, N. V., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62749 · Cited by 226 · see citing works

The third group of the B7‐ CD 28 immune checkpoint family: HHLA 2, TMIGD 2, B7x, and B7‐H3

Janakiram, M., Shah, U. A., Liu, W., Zhao, A., Schoenberg, M., & Zang, X. (2017) · Immunological Reviews · doi:10.1111/imr.12521 · Cited by 225 · see citing works

NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis

Glasner, A., Levi, A., Enk, J., Isaacson, B., Viukov, S. V., Orlanski, S., Scope, A., Neuman, T., Enk, C. D., Hanna, J. H., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.007 · Cited by 223 · see citing works

CAR-NK for tumor immunotherapy: Clinical transformation and future prospects

Wang, W., Jiang, J., & Wu, C. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.033 · Cited by 221 · see citing works

A Novel Phosphotyrosine Motif with a Critical Amino Acid at Position −2 for the SH2 Domain-mediated Activation of the Tyrosine Phosphatase SHP-1*

Burshtyn, D., Yang, W.-T., Yi, T., & Long, E. O. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.20.13066 · Cited by 219 · see citing works

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

Lussier, D. M., Johnson, J. L., Hingorani, P., & Blattman, J. N. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0067-z · Cited by 206 · see citing works

The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure

Garrity, D., Call, M. E., Feng, J. A., & Wucherpfennig, K. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502439102 · Cited by 206 · see citing works

FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy

Chen, X., Song, X., Li, K., & Zhang, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00292 · Cited by 177 · see citing works

Independent Modes of Natural Killing Distinguished in Mice Lacking Lag3

Miyazaki, T., Dierich, A., Benoist, C. O., & Mathis, D. J. (1996) · Science · doi:10.1126/science.272.5260.405 · Cited by 173 · see citing works

NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway

Horng, T., Bezbradica, J. S., & Medzhitov, R. M. (2007) · Nature Immunology · doi:10.1038/ni1524 · Cited by 169 · see citing works

Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma

Carlsten, M., Korde, N., Kotecha, R. R., Reger, R. N., Bor, S., Kazandjian, D. G., Landgren, O., & Childs, R. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1108 · Cited by 166 · see citing works

A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma

Federico, S. M., McCarville, M. B., Shulkin, B. L., Sondel, P. M., Hank, J. A., Hutson, P. R., Meagher, M. M., Shafer, A., Ng, C. Y., Leung, W. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0379 · Cited by 165 · see citing works

Enhanced In Vivo Growth of Lymphoma Tumors in the Absence of the NK-Activating Receptor NKp46/NCR1

Halfteck, G. G., Elboim, M., Gur, C., Achdout, H., Ghadially, H., & Mandelboim, O. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801878 · Cited by 162 · see citing works

Metabolic Regulation of Natural Killer Cell IFN-γ Production

Mah-Som, A. Y., & Cooper, M. A. (2016) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2016017387 · Cited by 160 · see citing works

Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo

Koh, C. Y., Blazar, B. R., George, T. C., Welniak, L. A., Capitini, C. M., Raziuddin, A., Murphy, W. J., & Bennett, M. (2001) · Blood · doi:10.1182/blood.v97.10.3132 · Cited by 159 · see citing works

Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells

Ruggeri, L., Urbani, E., André, P., Mancusi, A., Tosti, A., Topini, F., Bléry, M., Animobono, L., Romagné, F., Wagtmann, N. R., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.135301 · Cited by 156 · see citing works

Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults

Dobrenkov, K., Ostrovnaya, I., Gu, J., Cheung, I. Y., & Cheung, N. V. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26097 · Cited by 149 · see citing works

Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial

Lee, D. A., Denman, C. J., Rondón, G., Woodworth, G. G., Chen, J. J., Fisher, T. D., Kaur, I., Fernández-Viña, M., Cao, K., Ciurea, S. O., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.04.009 · Cited by 148 · see citing works

NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia

Locatelli, F., Pende, D., Falco, M., Chiesa, M. D., Moretta, A., & Moretta, L. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.04.009 · Cited by 145 · see citing works

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies

Vey, N., Karlin, L., Sadot‐Lebouvier, S., Broussais, F., Berton-Rigaud, D., Rey, J., Charbonnier, A., Marie, D., André, P., Paturel, C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24832 · Cited by 143 · see citing works

DNAM-1 Expression Marks an Alternative Program of NK Cell Maturation

Martinet, L., de Andrade, L. F., Guillerey, C., Lee, J. S., Liu, J., Souza-Fonseca-Guimarães, F., Hutchinson, D. S., Kolesnik, T. B., Nicholson, S. E., Huntington, N. D., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.006 · Cited by 142 · see citing works

DNAM‐1 control of natural killer cells functions through nectin and nectin‐like proteins

de Andrade, L. F., Smyth, M. J., & Martinet, L. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.95 · Cited by 142 · see citing works

Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness

Lemke, D., Pfenning, P., Sahm, F., Klein, A.-C., Kempf, T., Warnken, U. H., Schnölzer, M., Tudoran, R., Weller, M., Platten, M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0880 · Cited by 141 · see citing works

DNAM-1 controls NK cell activation via an ITT-like motif

Zhang, Z., Wu, N., Lü, Y., Davidson, D., Colonna, M., & Veillette, A. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150792 · Cited by 140 · see citing works

The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm

Lecocq, Q., Keyaerts, M., Devoogdt, N., & Breckpot, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010075 · Cited by 133 · see citing works

CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia.

Davila, M. L., & Brentjens, R. J. (2016) · PubMed · Cited by 128 · see citing works

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy

Simon, T., Hero, B., Faldum, A., Handgretinger, R., Schrappe, M., Klingebiel, T., & Berthold, F. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-21 · Cited by 128 · see citing works

Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group

Roberts, R. D., Lizardo, M. M., Reed, D. R., Hingorani, P., Glover, J., Allen‐Rhoades, W., Fan, T., Khanna, C., Sweet‐Cordero, E. A., Cash, T., et al. (2019) · Cancer · doi:10.1002/cncr.32351 · Cited by 127 · see citing works

Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial

Canter, R. J., Grossenbacher, S. K., Foltz, J. A., Sturgill, I. R., Park, J. S., Luna, J. I., Kent, M. S., Culp, W. T. N., Chen, M., Modiano, J. F., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0305-7 · Cited by 127 · see citing works

Humanized 3F8 Anti-G D2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma

Kushner, B. H., Cheung, I. Y., Modak, S. I., Basu, E. M., Roberts, S. S., & Cheung, N. V. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4005 · Cited by 127 · see citing works

NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways

Verhoeven, D. H. J., de Hooge, A. S. K., Mooiman, E., Santos, S. J., ten Dam, M. M., Gelderblom, H. A. J., Melief, C. J. M., Hogendoorn, P. C. W., Egeler, R. M., van Tol, M. J. D., et al. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.06.016 · Cited by 125 · see citing works

Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study

Yu, S., Huang, F., Wang, Y., Xu, Y., Yang, T., Fan, Z., Lin, R., Xu, N., Xuan, L., Ye, J., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0686-3 · Cited by 125 · see citing works

3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.

Cheung, N. V., Kushner, B. H., Yeh, S. D. J., & Larson, S. M. (1998) · International Journal of Oncology · doi:10.3892/ijo.12.6.1299 · Cited by 122 · see citing works

The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

Kendsersky, N. M., Lindsay, J., Kolb, E. A., Smith, M. A., Teicher, B. A., Erickson, S. W., Earley, E. J., Mosse, Y. P., Martinez, D., Pogoriler, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4221 · Cited by 120 · see citing works

Role of Common‐Gamma Chain Cytokines in NK Cell Development and Function: Perspectives for Immunotherapy

Meazza, R., Azzarone, B. G., Orengo, A. M., & Ferrini, S. (2011) · BioMed Research International · doi:10.1155/2011/861920 · Cited by 120 · see citing works

A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia

Nguyen, R., Wu, H., Pounds, S. B., Inaba, H., Ribeiro, R. C., Cullins, D. L., Rooney, B., Bell, T., Lacayo, N. J., Heym, K. M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0564-6 · Cited by 116 · see citing works

PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance

Dondero, A., Pastorino, F., Chiesa, M. D., Corrias, M. V., Morandi, F., Pistoia, V., Olive, D., Bellora, F., Locatelli, F., Castellano, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1064578 · Cited by 113 · see citing works

Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?

Hosseinkhani, N., Derakhshani, A., Kooshkaki, O., Shadbad, M. A., Hajiasgharzadeh, K., Baghbanzadeh, A., Safarpour, H., Mokhtarzadeh, A., Brunetti, O., Yue, S. C., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218305 · Cited by 110 · see citing works

Modulation of NK Cell Function by Genetically Coupled C-Type Lectin-Like Receptor/Ligand Pairs Encoded in the Human Natural Killer Gene Complex

Bartel, Y., Bauer, B., & Steinle, A. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00362 · Cited by 101 · see citing works

Tumor Immunoediting by NKp46

Elboim, M., Gazit, R., Gur, C., Ghadially, H., Betser-Cohen, G., & Mandelboim, O. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901644 · Cited by 96 · see citing works

Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells

Buddingh, E. P., Schilham, M. W., Ruslan, S. E. N., Berghuis, D., Szuhai, K., Suurmond, J., Taminiau, A. H. M., Gelderblom, H. A. J., Egeler, R. M., Serra, M., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0965-3 · Cited by 95 · see citing works

The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells

Rettinger, E., Kuçi, S., Naumann, I., Becker, P. S. A., Kreyenberg, H., Anzaghe, M., Willasch, A. M., Koehl, U., Bug, G., Ruthardt, M., et al. (2011) · Cytotherapy · doi:10.3109/14653249.2011.613931 · Cited by 95 · see citing works

Management of graft-versus-host disease

Arai, S., & Vogelsang, G. B. (2000) · Blood Reviews · doi:10.1054/blre.2000.0137 · Cited by 94 · see citing works

Immunoglobulin G Fc Receptor FcγRIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma

Weng, W., Negrin, R. S., Lavori, P. W., & Horning, S. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0274 · Cited by 93 · see citing works

Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing +T and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies

Muccio, L., Bertaina, A., Falco, M., Pende, D., Meazza, R., López‐Botet, M., Moretta, L., Locatelli, F., Moretta, A., & Chiesa, M. D. (2015) · Haematologica · doi:10.3324/haematol.2015.134155 · Cited by 93 · see citing works

Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study

Modak, S. I., Luduec, J.-B. L., Cheung, I. Y., Goldman, D. A., Ostrovnaya, I., Doubrovina, E. S., Basu, E. M., Kushner, B. H., Kramer, K., Roberts, S. S., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1461305 · Cited by 92 · see citing works

Spontaneous and induced tumor incidence in germfree "nude" mice.

Outzen, H. C., Custer, R. P., Eaton, G. J., & Prehn, R. T. (1975) · PubMed · Cited by 90 · see citing works

Going back to class I: MHC and immunotherapies for childhood cancer

Haworth, K. B., Leddon, J. L., Chen, C., Horwitz, E. M., Mackall, C. L., & Cripe, T. P. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25359 · Cited by 85 · see citing works

Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies

Shankar, K., Capitini, C. M., & Saha, K. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01741-4 · Cited by 85 · see citing works

IL‐2‐activated haploidentical NK cells restore NKG2D‐mediated NK‐cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA

Kloeß, S., Huenecke, S., Piechulek, D., Esser, R., Koch, J., Brehm, C., Soerensen, J., Gardlowski, T., Brinkmann, A., Bader, P., et al. (2010) · European Journal of Immunology · doi:10.1002/eji.201040568 · Cited by 83 · see citing works

Intracellular Signaling by the Killer Immunoglobulin-Like Receptors and Ly49

McVicar, D. W., & Burshtyn, D. N. (2001) · Science s STKE · doi:10.1126/stke.2001.75.re1 · Cited by 83 · see citing works

Ex Vivo Expanded Adaptive NK Cells Effectively Kill Primary Acute Lymphoblastic Leukemia Cells

Liu, L. L., Béziat, V., Oei, V. Y. S., Pfefferle, A., Schaffer, M., Lehmann, S., Hellström‐Lindberg, E., Söderhäll, S., Heyman, M. M., Grandér, D., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0296 · Cited by 79 · see citing works

DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by γδ T lymphocytes

Nussbaumer, O., Gruenbacher, G., Gander, H., & Thurnher, M. (2011) · Blood · doi:10.1182/blood-2011-01-328526 · Cited by 78 · see citing works

Haploidentical Stem Cell Transplantation in Patients with Pediatric Solid Tumors: Preliminary Results of a Pilot Study and Analysis of Graft versus Tumor Effects

Lang, P., Pfeiffer, M. M., Müller, I., Schumm, M., Ebinger, M., Kościelniak, E., Feuchtinger, T. F., Föll, J., Martin, D. D., & Handgretinger, R. (2006) · Klinische Pädiatrie · doi:10.1055/s-2006-942256 · Cited by 78 · see citing works

The Lectin-Like NK Cell Receptor Ly-49A Recognizes a Carbohydrate-Independent Epitope on Its MHC Class I Ligand

Matsumoto, N., Ribaudo, R. K., Abastado, J., Margulies, D. H., & Yokoyama, W. M. (1998) · Immunity · doi:10.1016/s1074-7613(00)80476-8 · Cited by 78 · see citing works

Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D–NKG2DL dependent manner

Fernández, L., Valentín, J., Zalacaín, M., Leung, W. H., Patiño‐García, A., & Pérez‐Martínez, A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.042 · Cited by 77 · see citing works

Adaptive NK cell reconstitution is associated with better clinical outcomes

Cichocki, F. M., Taras, E., Chiuppesi, F., Wagner, J. E., Blazar, B. R., Brunstein, C. G., Luo, X., Diamond, D. J., Cooley, S., Weisdorf, D. J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.125553 · Cited by 77 · see citing works

Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells

Wang, X., Jasinski, D. L., Medina, J. L., Spencer, D. M., Foster, A. E., & Bayle, J. H. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001510 · Cited by 74 · see citing works

Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia

Vela, M., Corral, D., Carrasco, P., Fernández, L., Valentín, J., González, B., Escudero, A., Balas, A., de Paz, R., Torres, J. M., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.033 · Cited by 74 · see citing works

Immune reconstitution after transplantation of autologous peripheral CD34+ cells: analysis of predictive factors and comparison with unselected progenitor transplants

Rutella, S., Rumi, C., Laurenti, L., Pierelli, L., Sorà, F., Sica, S., & Leone, G. G. M. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.01824.x · Cited by 73 · see citing works

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD 2 antibody ch14.18/CHO

Siebert, N., Zumpe, M., Jüttner, M., Troschke‐Meurer, S., & Lode, H. N. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1343775 · Cited by 71 · see citing works

NKp46 Clusters at the Immune Synapse and Regulates NK Cell Polarization

Hadad, U., Thauland, T. J., Martinez, O. M., Butte, M. J., Porgador, A., & Krams, S. M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00495 · Cited by 64 · see citing works

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group

Erbe, A. K., Wang, W., Carmichael, L. L., Kim, K., Mendonça, E. A., Song, Y., Hess, D., Reville, P. K., London, W. B., Naranjo, A. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1767 · Cited by 64 · see citing works

Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma

Moore, C. E., Eslin, D. E., Levy, A., Roberson, J. R., Giusti, V., & Sutphin, R. M. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22673 · Cited by 60 · see citing works

IL‐12/15/18‐preactivated NK cells suppress GvHD in a mouse model of mismatched hematopoietic cell transplantation

Hüber, C. M., Doisne, J., & Colucci, F. (2015) · European Journal of Immunology · doi:10.1002/eji.201445200 · Cited by 57 · see citing works

Ly49 receptors: evolution, genetic diversity, and impact on immunity

Rahim, M. M. A., & Makrigiannis, A. P. (2015) · Immunological Reviews · doi:10.1111/imr.12318 · Cited by 56 · see citing works

Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma

Ehlert, K., Hansjuergens, I., Zinke, A., Otto, S., Siebert, N., Henze, G., & Lode, H. N. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000540 · Cited by 50 · see citing works

c‐Cbl regulates MICA‐ but not ULBP2‐induced NKG2D down‐modulation in human NK cells

Molfetta, R., Quatrini, L., Capuano, C., Gasparrini, F., Zitti, B., Zingoni, A., Galandrini, R., Santoni, A., & Paolini, R. (2014) · European Journal of Immunology · doi:10.1002/eji.201444512 · Cited by 48 · see citing works

Nutlin-3a Enhances Natural Killer Cell–Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors

Veneziani, I., Infante, P., Ferretti, E., Melaiu, O., Battistelli, C., Lucarini, V., Compagnone, M., Nicoletti, C., Castellano, A., Petrini, S., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0313 · Cited by 48 · see citing works

Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2

Meazza, C., Cefalo, G., Massimino, M., Daolio, P. A., Pastorino, U., Scanagatta, P., Morosi, C., Podda, M. G., Ferrari, A., Terenziani, M., et al. (2017) · Medical Oncology · doi:10.1007/s12032-017-1052-9 · Cited by 47 · see citing works

Natural killer cell therapy in children with relapsed leukemia

Rubnitz, J. E., Inaba, H., Kang, G., Gan, K., Hartford, C. M., Triplett, B. M., Dallas, M. H., Shook, D. R., Gruber, T. A., Pui, C., et al. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25555 · Cited by 47 · see citing works

Ligand Binding to Inhibitory Killer Cell Ig-Like Receptors Induce Colocalization with Src Homology Domain 2-Containing Protein Tyrosine Phosphatase 1 and Interruption of Ongoing Activation Signals

Vyas, Y. M., Maniar, H. S., Lyddane, C., Sadelain, M., & Dupont, B. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.3.1571 · Cited by 46 · see citing works

Isolation and characterization of canine natural killer cells

Michael, H. T., Ito, D., McCullar, V., Zhang, B., Miller, J. S., & Modiano, J. F. (2013) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2013.06.013 · Cited by 46 · see citing works

Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial

Vey, N., Dumas, P., Récher, C., Gastaud, L., Lioure, B., Bulabois, C., Pautas, C., Marolleau, J., Leprêtre, S., Raffoux, E., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.889.889 · Cited by 40 · see citing works

2019 ASPHO ABSTRACTS

Chu, Y., Nayyar, G., Rosenblum, J., Lyngdoh, J., Cao, J., Amar, S., & Cairo, M. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27713 · Cited by 38 · see citing works

Human NKG2E Is Expressed and Forms an Intracytoplasmic Complex with CD94 and DAP12

Orbelyan, G. A., Tang, F., Sally, B., Solus, J. F., Meresse, B., Ciszewski, C., Grenier, J., Barreiro, L. B., Lanier, L. L., & Jabrì, B. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400556 · Cited by 36 · see citing works

Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance

Calvo, T., Reina-Ortiz, C., Giraldos, D., Gascón, M., Woods, D., Asenjo, J., Marco-Brualla, J., Azaceta, G., Izquierdo, I., Palomera, L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76051-z · Cited by 35 · see citing works

Expression of HLA‐A, B, C, β2‐microglobulin (β2m), HLA‐DR, ‐DP, ‐DQ and of HLA‐D‐associated invariant chain (Ii) in soft‐tissue tumors

Mechtersheimer, G., Staudter, M., Majdic, O., Dörken, B., Moldenhauer, G., & Möller, P. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910460512 · Cited by 34 · see citing works

Comparison of Phenotypic and Functional Characteristics Between Canine Non-B, Non-T Natural Killer Lymphocytes and CD3+CD5dimCD21− Cytotoxic Large Granular Lymphocytes

Lee, S.-H., Shin, D., Kim, Y., Kim, C.-J., Lee, J., Yoon, M. S., Uong, T. N. T., Yu, D., Jung, J., Cho, D., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00841 · Cited by 33 · see citing works

A nanoscale reorganization of the IL-15 receptor is triggered by NKG2D in a ligand-dependent manner

Bálint, Š., Lopes, F. B., & Davis, D. M. (2018) · Science Signaling · doi:10.1126/scisignal.aal3606 · Cited by 32 · see citing works

Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells

Boerman, G. H., Dam, M. M. V. O.-T., Kraal, K. C. J. M., Santos, S. J., Ball, L. M., Lankester, A. C., Schilham, M. W., Egeler, R. M., & van Tol, M. J. D. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1657-9 · Cited by 31 · see citing works

How ITAMs Inhibit Signaling

Ivashkiv, L. B. (2011) · Science Signaling · doi:10.1126/scisignal.2001917 · Cited by 31 · see citing works

The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma

Yuan, H., Liu, J., & Zhang, J. (2021) · Molecules · doi:10.3390/molecules26051392 · Cited by 30 · see citing works

NCR1 is an activating receptor expressed on a subset of canine NK cells

Grøndahl-Rosado, C., Boysen, P., Johansen, G. M., Brun‐Hansen, H., & Storset, A. K. (2016) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2016.05.001 · Cited by 28 · see citing works

Immunohistochemical Validation of Spontaneously Arising Canine Osteosarcoma as a Model for Human Osteosarcoma

Al-Khan, A. A., Gunn, H. J., Day, M. J., Tayebi, M., Ryan, S. D., Kuntz, C. A., Saad, E., Richardson, S. J., & Danks, J. A. (2017) · Journal of Comparative Pathology · doi:10.1016/j.jcpa.2017.07.005 · Cited by 28 · see citing works

Cellular Immunotherapy of Canine Cancer

Addissie, S., & Klingemann, H. (2018) · Veterinary Sciences · doi:10.3390/vetsci5040100 · Cited by 28 · see citing works

Programmed Death-Ligand 1 Expression in a Large Cohort of Pediatric Patients With Solid Tumor and Association With Clinicopathologic Features in Neuroblastoma

Saletta, F., Vilain, R. E., Gupta, A., Nagabushan, S., Yuksel, A., Catchpoole, D. R., Scolyer, R. A., Byrne, J. A., & McCowage, G. B. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00049 · Cited by 26 · see citing works

Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer

Judge, S. J., Yanagisawa, M., Sturgill, I. R., Bateni, S. B., Gingrich, A. A., Foltz, J. A., Lee, D. A., Modiano, J. F., Monjazeb, A. M., Culp, W. T. N., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0224775 · Cited by 25 · see citing works

Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients

Llosa, N. J., Cooke, K. R., Chen, A. R., Gamper, C. J., Klein, O. R., Zambidis, E. T., Luber, B. S., Rosner, G. L., Siegel, N. M., Holuba, M. J., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.08.012 · Cited by 25 · see citing works

KIR receptor‐ligand incompatibility predicts killing of osteosarcoma cell lines by allogeneic NK cells

Delgado, D. C., Webster, D. E., DeSantes, K. B., Durkin, E. T., & Shaaban, A. F. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22665 · Cited by 24 · see citing works

Phenotypic and Functional Characterization of NK Cells in αβT-Cell and B-Cell Depleted Haplo-HSCT to Cure Pediatric Patients with Acute Leukemia

Meazza, R., Falco, M., Loiacono, F., Canevali, P., Chiesa, M. D., Bertaina, A., Pagliara, D., Merli, P., Indio, V., Galaverna, F., et al. (2020) · Cancers · doi:10.3390/cancers12082187 · Cited by 21 · see citing works

Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients

Buddingh, E. P., Ruslan, S. E. N., Berghuis, D., Gelderblom, H. A. J., Anninga, J., Hogendoorn, P. C. W., Egeler, R. M., Schilham, M. W., & Lankester, A. C. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1232-6 · Cited by 19 · see citing works

PD‑L1/PD‑1 axis serves an important role in natural killer cell‑induced cytotoxicity in osteosarcoma

Zhang, M., Chen, L., Li, Y., & Kong, D. (2019) · Oncology Reports · doi:10.3892/or.2019.7299 · Cited by 18 · see citing works

Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewing’s sarcoma patients

Schlegel, P.-G., Feuchtinger, T. F., Nitschke-Gérard, C., Seidel, U. J. E., Lang, A.-M., Kyzirakos, C., Teltschik, H.-M., Ebinger, M., Schumm, M., Kościelniak, E., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.100 · Cited by 17 · see citing works

Characterization of MHC Class I and β‐2‐Microglobulin Expression in Pediatric Solid Malignancies to Guide Selection of Immune‐Based Therapeutic Trials

Haworth, K. B., Arnold, M., Pierson, C. R., Leddon, J. L., Kurmashev, D., Swain, H. M., Hutzen, B. J., Roberts, R. D., & Cripe, T. P. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25842 · Cited by 17 · see citing works

Expression of carcinoma, apoptosis, and cell‐death–related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells

Ray, A., Somanchi, S. S., Dastgheyb, N., Aquino‐López, A., Cobanoglu, Z. E., Geier, B., & Lee, D. A. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27783 · Cited by 16 · see citing works

NKG2H-Expressing T Cells Negatively Regulate Immune Responses

Dukovska, D., Fernández‐Soto, D., Valés‐Gómez, M., & Reyburn, H. T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00390 · Cited by 16 · see citing works

Early and Sustained Expansion of Adaptive Natural Killer Cells Following Haploidentical Transplantation and CTLA4Ig-Primed Donor Lymphocyte Infusions Dissociate Graft-versus-Leukemia and Graft-versus-Host Effects

Jaiswal, S. R., Chakraborty, S., Lakhchaura, R., Shashi, P., Mehta, A., Soni, M., & Chakrabarti, S. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2020.10.005 · Cited by 15 · see citing works

Phase II study of antidisialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma (AOST1421): A report from the Children’s Oncology Group.

Hingorani, P., Krailo, M., Buxton, A. B., Hutson, P. R., Davis, J., Janeway, K. A., Gorlick, R. G., & Isakoff, M. S. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.10508 · Cited by 15 · see citing works

[Evaluation of selected parameters of cellular immunity in children with osteosarcoma at diagnosis].

Markiewicz, K., Zeman, K., Kozar, A., Gołębiowska-Wawrzyniak, M., & Woźniak, W. (2012) · PubMed · Cited by 14 · see citing works

Allogeneic stem cell transplantation for renal cell carcinoma

Bregni, M., Herr, W., Blaise, D., & The Solid Tumor Working Party of the, E. B. M. T. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.12 · Cited by 14 · see citing works

Activating and inhibitory receptors and their role in natural killer cell function.

Srivastava, R. M., Savithri, B., & Khar, A. (2003) · PubMed · Cited by 13 · see citing works

Programmed cell death protein 1 on natural killer cells: fact or fiction?

Cho, M. M., Quamine, A. E., Olsen, M. R., & Capitini, C. M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137051 · Cited by 13 · see citing works

CD155 is involved in NK-cell mediated lysis of human hepatoblastoma in vitro

Pfeiffer, M. M. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/e346 · Cited by 12 · see citing works

Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells

Kim, Y., Lee, S.-H., Kim, C.-J., Lee, J., Yu, D., Ahn, S.-M., Shin, D., & Kim, S. (2019) · BMC Veterinary Research · doi:10.1186/s12917-019-2068-5 · Cited by 11 · see citing works

Dissecting the NK Cell Population in Hematological Cancers Confirms the Presence of Tumor Cells and Their Impact on NK Population Function

Vo, D.-N., Constantinides, M., Allende-Vega, N., Alexia, C., Cartron, G., & Villalba, M. (2020) · Vaccines · doi:10.3390/vaccines8040727 · Cited by 9 · see citing works

Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after

Tykodi, S. S., Sandmaier, B. M., Warren, E. H., & Thompson, J. A. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.566855 · Cited by 8 · see citing works

Immunological Sculpting

Donatelli, S. S., & Djeu, J. Y. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00009-9 · Cited by 3 · see citing works

Advances on immunotherapy for osteosarcoma

Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270 · see citing works

Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells

Colucci, M., Zumerle, S., Bressan, S., Gianfanti, F., Troiani, M., Valdata, A., D’Ambrosio, M., Pasquini, E., Varesi, A., Cogo, F., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.004 · Cited by 85 · see citing works

Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis

Nirala, B. K., Yamamichi, T., Petrescu, D. I., Shafin, T. N., & Yustein, J. T. (2023) · Cancers · doi:10.3390/cancers15205108 · Cited by 51 · see citing works

Epigenetic regulators combined with tumour immunotherapy: current status and perspectives

Zhang, H., Pang, Y., Yi, L., Wang, X., Wei, P., Wang, H., & Lin, S. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01856-6 · Cited by 43 · see citing works

The immune landscape of solid pediatric tumors

Sherif, S., Roelands, J. P., Mifsud, W., Ahmed, E. I., Raynaud, C. M., Rinchai, D., Sathappan, A., Maaz, A. U. R., Saleh, A., Özer, E., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02397-z · Cited by 38 · see citing works

From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review

Regmi, M., Wang, Y., Liu, W., Dai, Y., Liu, S., Ma, K., Lin, G., Yang, J., Liu, H., Wu, J., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02973-5 · Cited by 24 · see citing works

Spatial multiplexed immunofluorescence analysis reveals coordinated cellular networks associated with overall survival in metastatic osteosarcoma

Lacinski, R. A., Dziadowicz, S. A., Melemai, V. K., Fitzpatrick, B., Pisquiy, J. J., Heim, T. E., Lohse, I., Schoedel, K. E., Llosa, N. J., Weiss, K. R., et al. (2024) · Bone Research · doi:10.1038/s41413-024-00359-z · Cited by 22 · see citing works

Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future

Morel, V. J., Rössler, J. K., & Bernasconi, M. (2024) · Medicinal Research Reviews · doi:10.1002/med.22059 · Cited by 15 · see citing works

CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma

Cho, M. M., Song, L., Quamine, A. E., Szewc, F., Shi, L., Ebben, J. D., Turicek, D. P., Kline, J. M., Burpee, D. M., Lafeber, E. O., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008755 · Cited by 13 · see citing works

Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma

Jacob, M., Wiedemann, S., Brücher, D., Pieper, N. M., Birkhold, M., Särchen, V., Jeroch, J., Demes, M. C., Gretser, S., Braun, Y., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02430-8 · Cited by 13 · see citing works

Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives

Hu, Y., Yang, R., Ni, S., & Song, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1485053 · Cited by 11 · see citing works

Panobinostat enhances NK cell cytotoxicity in soft tissue sarcoma

Lu, X., Liu, M., Yang, J., Que, Y., & Zhang, X. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac068 · Cited by 11 · see citing works

Transcriptome Analysis of Tumor-Infiltrating Lymphocytes Identifies NK Cell Gene Signatures Associated With Lymphocyte Infiltration and Survival in Soft Tissue Sarcomas

Judge, S. J., Bloomstein, J. D., Sholevar, C. J., Darrow, M. A., Stoffel, K. M., Vick, L. V., Dunai, C., Cruz, S. M., Razmara, A. M., Monjazeb, A. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.893177 · Cited by 10 · see citing works

Soluble NKG2D ligands impair CD8+ T cell antitumor function dependent of NKG2D downregulation in neuroblastoma

Zhang, Y., Luo, F., & Dong, K. (2023) · Oncology Letters · doi:10.3892/ol.2023.13883 · Cited by 10 · see citing works

The role of neutrophils in osteosarcoma: insights from laboratory to clinic

Xia, M. X., Han, Y., Sun, L., Li, D., Zhu, C., & Li, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1490712 · Cited by 9 · see citing works

Natural killer cell-based therapies in neuroblastoma

Ghasempour, A., Mohseni, R., Sharif, P. M., & Hamidieh, A. A. (2024) · Cellular Immunology · doi:10.1016/j.cellimm.2024.104898 · Cited by 8 · see citing works

Immunotherapy for neuroblastoma using mRNA vaccines

Ahmed, T. (2022) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2022.100033 · Cited by 8 · see citing works

Epigenetic modulation elicits an NK cell-mediated immune response in urothelial carcinoma

Kumari, H., Chen, C.-N., Shih, H.-A., Yeh, C.-C., Tseng, T.-Y., Tsai, H.-F., Low, J. T., Chan, C. P., Lin, G., Huang, W.-H., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01264-9 · Cited by 4 · see citing works

Strategies for Potentiating NK-Mediated Neuroblastoma Surveillance in Autologous or HLA-Haploidentical Hematopoietic Stem Cell Transplants

Bottino, C., Chiesa, M. D., Sorrentino, S., Morini, M., Vitale, C., Dondero, A., Tondo, A., Conte, M., Garaventa, A., & Castriconi, R. (2022) · Cancers · doi:10.3390/cancers14194548 · Cited by 4 · see citing works

LPS combined with CD47mAb enhances the anti‑osteosarcoma ability of macrophages

Yuan, P., Que, Y., Liu, Y., He, P., Guo, Z., & Hu, Y. S. (2023) · Oncology Letters · doi:10.3892/ol.2023.13777 · Cited by 3 · see citing works

Experimental and Clinical Advances in Counteracting Progression of Solid Cancers

Nicolini, A. (2023) · Cancers · doi:10.3390/cancers15071956 · Cited by 3 · see citing works

A conceptual blueprint for “turning cold to hot” in Osteosarcoma: from TME stratification hypotheses to adaptive therapeutic prospects

Yang, B., Liu, S., Liu, B., Ye, T., Ma, X., & Song, T. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02883-3 · Cited by 2 · see citing works

Emerging Role and Mechanism of circRNAs in Pediatric Malignant Solid Tumors

Shen, Q., Liu, X., Li, W., Zhao, X., Li, T., Zhou, K., & Zhou, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.820936 · Cited by 2 · see citing works

Tumor–Immune Interactions in Pediatric Oral Rhabdomyosarcoma: A Narrative Review on Immuno-Oncology and Emerging Therapies

Meligy, O. E., Elemam, N. M., Hassan, W. A., & Talaat, I. M. (2025) · Children · doi:10.3390/children12091249 · Cited by 1 · see citing works

Paediatric therapeutic development workshop on osteosarcoma

Baxter, J. S., Montiel-Equihua, C., Molenaar, J. J., Berlanga, P., Bishop, M. W., Blanc, P., Campbell-Hewson, Q., Casanova, M., Cortés‐Ciriano, I., Crompton, B. D., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03572-1 · Cited by 1 · see citing works

Anti-dysplastic Effect of Nettle Extract and Its Nano-formulation on 7,12-Dimethylbenz[a]anthracene Induced Hamster Buccal Pouch Carcinogenesis

Ezzat, S. K., & Elsherbini, A. M. (2022) · Mansoura Journal of Dentistry · doi:10.21608/mjd.2022.155022.1072 · Cited by 1 · see citing works

Additional file 1 of The immune landscape of solid pediatric tumors

Sherif, S., Roelands, J. P., Mifsud, W., Ahmed, E. I., Raynaud, C. M., Rinchai, D., Sathappan, A., Maaz, A., Saleh, A., Ozer, E., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20056669

Additional file 7 of The immune landscape of solid pediatric tumors

Sherif, S., Roelands, J. P., Mifsud, W., Ahmed, E. I., Raynaud, C. M., Rinchai, D., Sathappan, A., Maaz, A., Saleh, A., Ozer, E., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20056687

Additional file 2 of The immune landscape of solid pediatric tumors

Sherif, S., Roelands, J. P., Mifsud, W., Ahmed, E. I., Raynaud, C. M., Rinchai, D., Sathappan, A., Maaz, A., Saleh, A., Ozer, E., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20056672

Additional file 6 of The immune landscape of solid pediatric tumors

Sherif, S., Roelands, J. P., Mifsud, W., Ahmed, E. I., Raynaud, C. M., Rinchai, D., Sathappan, A., Maaz, A., Saleh, A., Ozer, E., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20056684

Additional file 4 of The immune landscape of solid pediatric tumors

Sherif, S., Roelands, J. P., Mifsud, W., Ahmed, E. I., Raynaud, C. M., Rinchai, D., Sathappan, A., Maaz, A., Saleh, A., Ozer, E., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20056678

Additional file 5 of The immune landscape of solid pediatric tumors

Sherif, S., Roelands, J. P., Mifsud, W., Ahmed, E. I., Raynaud, C. M., Rinchai, D., Sathappan, A., Maaz, A., Saleh, A., Ozer, E., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20056681

Additional file 3 of The immune landscape of solid pediatric tumors

Sherif, S., Roelands, J. P., Mifsud, W., Ahmed, E. I., Raynaud, C. M., Rinchai, D., Sathappan, A., Maaz, A., Saleh, A., Ozer, E., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20056675

Modulation de la réponse innée par les alginates de calcium au cours de la cicatrisation cutanée

Adib, Y. (2022) · doi:10.70675/aa3b73b1z32edz4966zafebz4046bf6f3adf

Targeted Therapies in Neuroblastoma: A History and a View to the Future

Shah, N. (2026) · Cancers · doi:10.3390/cancers18111742

Safety and Feasibility of Infusing Ex Vivo Expanded Allogeneic Canine Natural Killer Cells for the Treatment of Metastatic Solid Tumours

Weisnicht, A. M., Szewc, F., Cho, M. M., Cheng, H.-Y. H., Ganesh, S., Mahoney, L., Fox, K. C., Smith, P. R., Olsen, M., Richards, R. M., et al. (2026) · Veterinary and Comparative Oncology · doi:10.1111/vco.70091

Gene-based immunotherapy in osteosarcoma: from oncolytic vectors to engineered immune cells

Jia, J., Xie, W., Zhou, J., Wu, W., & Zhou, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1920347

Epigenetic reprogramming of NK cell-mediated antitumor immunity in urothelial carcinoma: a mini-review

Kumari, H., Chou, C., Lee, Y.-T., Shen, C.-H., & Chan, M. W. Y. (2026) · Experimental Biology and Medicine · doi:10.3389/ebm.2026.11373

Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors

Nayyar, G., Chu, Y., & Cairo, M. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00051 · Cited by 177 · see citing works

The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers

Kimpo, M. S., Oh, B. L. Z., & Lee, S. Y. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0837-8 · Cited by 26 · see citing works

Natural killer cells as immunotherapeutic effectors for solid tumors

Matosevic, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822620-9.00014-8

Beyond CAR-T cells: Natural killer cells immunotherapy

Sánchez, M. D. C., Fernández, L., & Pérez‐Martínez, A. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.08.004 · Cited by 3 · see citing works

NK Cell-based Immunotherapies in Pediatric Oncology

McDowell, K. A., Hank, J. A., DeSantes, K. B., Capitini, C. M., Otto, M., & Sondel, P. M. (2015) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000303 · Cited by 19 · see citing works